Recently, PCSK9 inhibitor phase III studies, e.g., FOURIER and ODYSSEY randomized trials, reported no significant increase in hemorrhagic stroke among the study population despite profound LDL-C reduction. The gene discussed is PCSK9; the disease is hemorrhagic stroke.